Drug intelligence / Profile preview

IA-301

Development stage: Unknown
Lead developer: ImmuneAGE Bio
Modality: Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

IA-301 is a hematopoietic stem cell therapy initially developed by ImmuneAGE Bio. It is currently in the discovery phase of development and targets immune system diseases and infectious diseases, with active indications including bone marrow transplant rejection, autoimmune diseases, and infectious diseases. The specific mechanism of action and molecular targets have not been disclosed publicly as of the latest update. The therapy aims to modulate or restore immune function through hematopoietic stem cell transplantation or related approaches.

Beyond the preview

Go deeper on IA-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IA-301.

Explore the full profile